This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Celldex Therapeutics, Inc.
Drug Names(s): CG53135, Fibroblast Growth Factor-20, FGF-20
Description: CG53135 is a novel investigational protein therapeutic (FGF-20) that promotes both epithelial and mesenchymal cell proliferation in vitro and demonstrated activity in multiple animal models.
Deal Structure: CG53135 was originally developed by CuraGen.
In May 2009, Celldex Therapeutics announced it entered into a definitive agreement to acquire CuraGen. In October 2009, Celldex Therapeutics announced the successful completion of its acquisition of CuraGen Corporation.
Pink Sheet CuraGen velafermin
Additional information available to subscribers only: